MalarVx Overview
- Founded
- 2012
- Status
- Private
- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $1.05M
- Investors
- 1
MalarVx General Information
Description
Operator of a bio-pharmaceutical company. The company is focused on the development of in vitro culture systems for the malaria parasite which will lead to the development of an effective whole-parasite vaccine.
Contact Information
Primary Industry
Other Healthcare Services
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
- 307 Westlake Avenue North
- Suite 200
- Seattle, WA 98109
- United States
+1 (206) 000-0000
MalarVx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 21-Jun-2017 | $1.05M | 00.00 | Completed | Startup | |
| 1. Angel (individual) | 23-Nov-2015 | 00000 | 00000 | Completed | Startup |
MalarVx Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| James Davie | Co-Founder, President & Chief Executive Officer | ||
| Paul Harris Ph.D | Co-Founder & Vice President, Product Development |
MalarVx Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Keiretsu Forum | Venture Capital | Minority | 000 0000 | 000000 0 |